Boston Financial Mangement LLC Has $3.86 Million Stake in Amgen, Inc. (AMGN)

Boston Financial Mangement LLC trimmed its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 12.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,823 shares of the medical research company’s stock after selling 2,884 shares during the quarter. Boston Financial Mangement LLC’s holdings in Amgen were worth $3,859,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Arlington Partners LLC increased its holdings in Amgen by 86.7% in the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after buying an additional 65 shares during the last quarter. Massey Quick Simon & CO. LLC boosted its stake in Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 135 shares during the period. Contravisory Investment Management Inc. acquired a new position in Amgen in the fourth quarter valued at approximately $50,000. Lavaca Capital LLC acquired a new position in Amgen in the fourth quarter valued at approximately $78,000. Finally, Moody National Bank Trust Division acquired a new position in Amgen in the fourth quarter valued at approximately $81,000. 81.79% of the stock is currently owned by institutional investors and hedge funds.

Get Amgen alerts:

Shares of NASDAQ AMGN opened at $188.34 on Tuesday. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57. The company has a market cap of $120.01 billion, a PE ratio of 13.08, a price-to-earnings-growth ratio of 2.09 and a beta of 1.21. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period in the previous year, the firm posted $2.89 earnings per share. On average, analysts predict that Amgen, Inc. will post 13.93 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.32. This represents a $5.80 annualized dividend and a dividend yield of 3.08%. Amgen’s payout ratio is currently 36.67%.

A number of brokerages have commented on AMGN. Mizuho restated a “buy” rating and issued a $211.00 target price on shares of Amgen in a research note on Wednesday, February 13th. Royal Bank of Canada restated a “neutral” rating on shares of Amgen in a research note on Friday, February 1st. Leerink Swann decreased their target price on Amgen from $200.00 to $192.00 and set a “market perform” rating for the company in a research note on Wednesday, January 30th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $190.00 target price on shares of Amgen in a research note on Wednesday, January 30th. Finally, BidaskClub downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 29th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $205.77.

In other news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the transaction, the director now owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,777 shares of company stock valued at $4,648,718. Insiders own 0.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Boston Financial Mangement LLC Has $3.86 Million Stake in Amgen, Inc. (AMGN)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4162787/boston-financial-mangement-llc-has-3-86-million-stake-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: Why do corrections happen?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).